Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Helius Medical Technologies Inc (NASDAQ: HSDT) closed the day trading at $0.37 down -22.05% from the previous closing price of $0.48. In other words, the price has decreased by -$22.05 from its previous closing price. On the day, 0.81 million shares were traded. HSDT stock price reached its highest trading level at $0.4875 during the session, while it also had its lowest trading level at $0.373.
Ratios:
For a better understanding of HSDT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.80 and its Current Ratio is at 4.20. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Noble Capital Markets on March 24, 2021, initiated with a Outperform rating and assigned the stock a target price of $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 14 ’23 when ANDREEFF DANE bought 5,000 shares for $8.10 per share. The transaction valued at 40,475 led to the insider holds 16,512 shares of the business.
ANDREEFF DANE bought 2,006 shares of HSDT for $12,935 on Dec 01 ’23. The President and CEO now owns 13,685 shares after completing the transaction at $6.45 per share. On Nov 30 ’23, another insider, ANDREEFF DANE, who serves as the President and CEO of the company, bought 2,000 shares for $6.37 each. As a result, the insider paid 12,741 and bolstered with 12,551 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HSDT now has a Market Capitalization of 1337856 and an Enterprise Value of -5014145. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.27 while its Price-to-Book (P/B) ratio in mrq is 0.19. Its current Enterprise Value per Revenue stands at -8.441 whereas that against EBITDA is 0.424.
Stock Price History:
Over the past 52 weeks, HSDT has reached a high of $9.50, while it has fallen to a 52-week low of $0.45. The 50-Day Moving Average of the stock is -46.98%, while the 200-Day Moving Average is calculated to be -88.13%.
Shares Statistics:
Over the past 3-months, HSDT traded about 236.31K shares per day on average, while over the past 10 days, HSDT traded about 128960 shares per day. A total of 3.58M shares are outstanding, with a floating share count of 3.52M. Insiders hold about 1.48% of the company’s shares, while institutions hold 5.10% stake in the company. Shares short for HSDT as of 1727654400 were 59173 with a Short Ratio of 0.25, compared to 1724976000 on 33457. Therefore, it implies a Short% of Shares Outstanding of 59173 and a Short% of Float of 1.67.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 1.0 analysts currently analyzing and rating the stock of Helius Medical Technologies Inc (HSDT).The consensus estimate for the next quarter is -$0.88, with high estimates of -$0.88 and low estimates of -$0.88.
Analysts are recommending an EPS of between -$5.66 and -$5.66 for the fiscal current year, implying an average EPS of -$5.66. EPS for the following year is -$2.38, with 1.0 analysts recommending between -$2.38 and -$2.38.
Revenue Estimates
1 analysts predict $150k in revenue for the current quarter. It ranges from a high estimate of $150k to a low estimate of $150k. As of the current estimate, Helius Medical Technologies Inc’s year-ago sales were $143kFor the next quarter, 1 analysts are estimating revenue of $270k. There is a high estimate of $270k for the next quarter, whereas the lowest estimate is $270k.
A total of 1 analysts have provided revenue estimates for HSDT’s current fiscal year. The highest revenue estimate was $730k, while the lowest revenue estimate was $730k, resulting in an average revenue estimate of $730k. In the same quarter a year ago, actual revenue was $644kBased on 1 analysts’ estimates, the company’s revenue will be $1.31M in the next fiscal year. The high estimate is $1.31M and the low estimate is $1.31M.
